Quantum-Si (QSI) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Technology and innovation roadmap

• Launched first next-generation protein sequencing platform, moving from controlled to full commercial launch in Q2 2023.

• Sequencing kit chemistry improved rapidly, now at version 3, with over 5.5-fold increase in sequencing output since version 1.

• All new chemistry, software, and library prep kits remain compatible with existing hardware, with future hardware updates to be discussed at year-end analyst day.

• Innovation cycles target improvements in library prep, sequencing chemistry, and software every 6–9 months.

• Software and workflow enhancements address data complexity and expand application capabilities.

Commercialization and market adoption

• Initial placements focused on academic research centers, with recent expansion into pharma and biotech sectors.

• Academic customers show episodic consumable purchasing, while pharma/biotech clients demonstrate more consistent reorder patterns.

• Peer-to-peer networking and conference presentations are building awareness and credibility.

• Commercial team to expand by about 10 people by year-end to increase market reach.

• Direct sales model in US and Western Europe, with channel partners in other regions.

Applications and customer use cases

• Academic interest centers on variant calling and post-translational modifications (PTMs), supporting protein engineering and translational studies.

• Pharma and biotech customers focus on protein barcoding for high-throughput screening, including in vivo applications.

• New library prep kits address broader protein types and barcoding workflows, based on customer feedback.

• Technology enables detection of isoforms and PTMs not accessible by mass spectrometry, providing complementary and novel capabilities.